Literature DB >> 5082125

Anticoagulant therapy for senile dementia.

J Ratner, G Rosenberg, V A Kral, F Engelsmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5082125     DOI： 10.1111/j.1532-5415.1972.tb00758.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  9 in total

1.  Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model.

Authors:  Marta Cortes-Canteli; Anna Kruyer; Irene Fernandez-Nueda; Ana Marcos-Diaz; Carlos Ceron; Allison T Richards; Odella C Jno-Charles; Ignacio Rodriguez; Sergio Callejas; Erin H Norris; Javier Sanchez-Gonzalez; Jesus Ruiz-Cabello; Borja Ibanez; Sidney Strickland; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2019-10-15       Impact factor: 24.094

2.  Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Justin Paul; Erin H Norris; Robert Bronstein; Hyung Jin Ahn; Daria Zamolodchikov; Shivaprasad Bhuvanendran; Katherine M Fenz; Sidney Strickland
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

3.  The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.

Authors:  D Zamolodchikov; T Renné; S Strickland
Journal:  J Thromb Haemost       Date:  2016-02-29       Impact factor: 5.824

Review 4.  Fibrinogen and altered hemostasis in Alzheimer's disease.

Authors:  Marta Cortes-Canteli; Daria Zamolodchikov; Hyung Jin Ahn; Sidney Strickland; Erin H Norris
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 5.  Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.

Authors:  Klaus Grossmann
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

6.  The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy.

Authors:  Pradeep K Singh; Ana Badimon; Zu-Lin Chen; Sidney Strickland; Erin H Norris
Journal:  Res Pract Thromb Haemost       Date:  2021-05-03

Review 7.  Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  Biomedicines       Date:  2022-08-04

8.  A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice.

Authors:  Hyung Jin Ahn; J Fraser Glickman; Ka Lai Poon; Daria Zamolodchikov; Odella C Jno-Charles; Erin H Norris; Sidney Strickland
Journal:  J Exp Med       Date:  2014-05-12       Impact factor: 14.307

9.  Anticoagulants for Treatment of Alzheimer's Disease.

Authors:  Klaus Grossmann
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.